Role of TGF-β in Melanoma

Author(s): A. Busse, U. Keilholz

Journal Name: Current Pharmaceutical Biotechnology

Volume 12 , Issue 12 , 2011

Become EABM
Become Reviewer
Call for Editor


Human malignant melanoma is highly resistant to chemotherapy and current immunotherapeutic approaches induce long term remission only in the minority of patients. The transforming growth factor-β (TGF-β) has attracted much attention as a therapeutic target because it plays an important and pleiotropic role in melanoma progression. TGF-β is a multifunctional cytokine involved in the regulation of many cellular processes including cell proliferation, differentiation and survival. Resistance to the growth inhibitory effects of TGF-β without alterations of TGF-β signaling molecules is characteristic of cutaneous melanoma. Melanoma produces increasing amounts of TGF-βwith disease progression, inhibiting immune responses and providing an optimal microenvironment for undisturbed tumor growth. In addition, TGF-β exerts its tumor promoting functions via direct effects on tumor cell motility and invasiveness and indirectly by modulating tumor stroma and extracellular matrix, supporting angiogenesis and inhibiting immune surveillance. TGF-β acts through multiple intracellular signaling pathways and the outcome of TGF-β signaling is context-dependent. Defining the impact of the different TGF-β signaling pathways on melanoma progression will help to identify suitable therapeutic targets. Here we review the current knowledge of TGF-β in melanoma and discuss recent therapeutic approaches targeting the TGF-β pathway.

Keywords: Melanoma, TGF-β, immunosuppression, growth resistance, invasion, angiogenesis, metastasis, inhibiting immune surveillance, therapeutic targets, human tumors, Cutaneous melanoma, cyclin-dependent kinase (CDK), various immunosuppressive mechanisms, melanocytes, melanoma growth

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [2165 - 2175]
Pages: 11
DOI: 10.2174/138920111798808437
Price: $65

Article Metrics

PDF: 57